Hemostatic concomitants of syndrome X.
The elevated risk factors classically associated with Syndrome X do not adequately explain the increased cardiovascular risk linked to insulin resistance. Considerable indirect evidence and more limited direct evidence suggests that increases in certain prognostically significant hemostatic variables--notably plasma fibrinogen, factor VII coagulant activity, and plasminogen activator inhibitor-1 levels--may be concomitants of Syndrome X. Increased platelet aggregability, and a reduced capacity of vascular endothelium for prostacyclin generation, may also be associated with insulin resistance. Large clinical studies, involving quantification of insulin sensitivity and measurement of hemostatic variables, are required to test this hypothesis. It is unlikely that hyperinsulinemia mediates the connections between insulin resistance and hemostatic variables (or indeed other risk factors in Syndrome X). In light of the remarkably broad impact of insulin resistance on cardiovascular risk factors, promotion of optimal insulin sensitivity should assume a central role in preventive cardiology.
McCarty
M F
MF
Nutrition 21, San Diego, CA 92117, USA.
D000818:Animals; D000941:Antigens / Q000378:metabolism; D001792:Blood Platelets / Q000502:physiology; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000503:physiopathology; D011464:Epoprostenol / Q000097:blood; D005167:Factor VII / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006487:Hemostasis; D006801:Humans; D007333:Insulin Resistance; D017566:Microvascular Angina / Q000097:blood* / Q000503:physiopathology; D008954:Models, Biological; D008955:Models, Cardiovascular; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D012307:Risk Factors
D000941:Antigens; D017395:Plasminogen Activator Inhibitor 1; C042580:factor VII clotting antigen; D005167:Factor VII; D005340:Fibrinogen; D011464:Epoprostenol